cetuximab (Erbitux)

01/01/2013 - "In the CRYSTAL study adding cetuximab to first-line FOLFIRI significantly improved outcome in patients with KRAS wild-type metastatic colorectal cancer. "
04/01/2010 - "In subgroup analysis, in colorectal cancer, there was a significant improvement of PFS (0.72, 0.66-0.78), OS (0.90, 0.81-1.00), and ORR in the cetuximab group (1.36, 1.15-1.60). "
06/01/2015 - "We aimed to better clarify the role of germline variants of the FCG2 receptor, FCGR2A-H131R and FCGR3A-V158F, on the therapeutic efficacy of cetuximab in metastatic colorectal cancer (mCRC). "
05/20/2008 - "Cetuximab improved overall survival in colorectal cancer patients in whom other treatments had failed."
12/01/2011 - "KRAS mutation status is being used as the sole biomarker to predict therapeutic efficacy of cetuximab in metastatic colorectal cancer (mCRC). "

04/01/2014 - "Despite efficacy in preclinical HNSCC models, cetuximab is only effective in a subset of HNSCC patients, most likely due to the high heterogeneity of this cancer. "
01/01/2010 - "The mice receiving MnSOD-PL, C225, TPZ plus 14 Gy had the best outcome with 0.7+/-0.1 fold increase in tumor volume by 10 days (p=0.015) compared to irradiation only. "
03/01/2015 - "In the first-line treatment of mCRC, patients with RAS wild-type tumors derived a significant benefit from the addition of cetuximab to FOLFIRI; patients with RAS tumor mutations did not. "
11/03/2014 - "In the subsequent in vivo evaluation, (64)Cu-CB-TE1K1P-PEG4-click-cetuximab demonstrated more rapid renal clearance with a higher tumor/nontumor ratio than other (64)Cu-labeled cetuximab conjugates, and it shows the greatest promise for imaging and therapy of EGFR-positive tumors. "
09/01/2011 - "Importantly, serial imaging of MDA-MB-468 tumors responding to cetuximab therapy could detect a significant reduction of tumor uptake that was paralleled by downregulation of EGFR expression. "

04/01/2010 - "In non-small-cell lung cancer, there was a significant improvement of OS (0.86, 0.76-0.96) in the cetuximab group, and no difference on PFS (0.82, 0.64-1.07) and ORR (1.56, 0.85-2.88). "
12/01/2012 - "A clinical study in non-small cell lung cancer patients demonstrated a positive correlation between EGFR expression levels and the therapeutic efficacy of the EGFR mAb cetuximab. "
10/01/2008 - "Cetuximab: potential role as first-line treatment for advanced non-small cell lung cancer."
06/01/2010 - "This paper summarizes the phase II and III clinical trial experience with cetuximab in the first-line treatment of advanced non-small cell lung cancer (NSCLC). "
01/01/2014 - "Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating."

08/01/2015 - "The efficacy of cetuximab-based BRT in locally advanced head and neck squamous cell carcinomas has been established. "
10/01/2014 - "Efficacy of cetuximab in the treatment of squamous cell carcinoma."
01/01/2014 - "Cetuximab (Cx) + radiation therapy (RT) is well-tolerated and has improved survival in patients (pts) with locoregionally advanced head and neck squamous cell carcinomas (LA-HNSCC). "
12/01/2011 - "Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma--a report of eight cases."
01/01/2015 - "Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) on the UPCI 08-013 NCT01218048 trial were treated with single-agent cetuximab before surgery. "

01/01/2006 - "Indeed, one of the more striking clinical results in this field has been recently achieved by combining an EGFR inhibitor (cetuximab) with radiation in the treatment of advanced head and neck cancer patients. "
06/01/2015 - "The EGFR-targeted antibody cetuximab is effective against head and neck cancer (HNSCC), but in only 15% to 20% of patients, and the variability and extent of cetuximab-mediated cellular immunity is not fully understood. "
03/01/2009 - "We discuss the results of the phase III EXTREME (Erbitux in First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer) trial. "
01/01/2015 - "Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients."
06/01/2014 - "(Regarding Lartigau et al.: Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer)."